1-deamino-/4-valine-8-D-arginine/-vasopressin (dVDAVP), a new synthetic vasopressin analog for treating diabetes insipidus.
The effects of LVP, dDAVP, and dVDAVP on the water excretion of 14 vasopressin-sensitive and 2 ADH-resistant patients with diabetes insipidus were studied and compared. Findings showed that dDAVP and dVDAVP decreased the diuresis of all ADH-sensitive patients, and in those with diabetes insipidus, more markedly (7.6-fold) and for a longer duration (3.3-fold) than did LVP. From a comparison of the results, dVDAVP is at present one of the most effective preparations for reduction of polyuria in patients with ADH-sensitive diabetes insipidus.
D000328:Adult; D000368:Aged; D001127:Arginine Vasopressin / Q000031:analogs & derivatives*; D003894:Deamino Arginine Vasopressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004231:Diuresis / Q000187:drug effects; D005260:Female; D006801:Humans; D008236:Lypressin / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use
D001127:Arginine Vasopressin; D008236:Lypressin; C007223:vasopressin, 1-deamino-4-Val-8-Arg-; D003894:Deamino Arginine Vasopressin; D014633:Valine